U.S. flag

An official website of the United States government

GTR Home > Tests > High-Resolution Rapid Microarray (CGH and SNP)

Overview

Test order codeHelp: 110

Test name

Help

High-Resolution Rapid Microarray (CGH and SNP)

Purpose of the test

Help

This is a clinical test intended for Help: Diagnosis

Condition

Help

Click Indication tab for more information.

How to order

Help

For specimen requirements and handling instructions please visit: https://www.allelediagnostics.com/ordering/sample-requirements/. Allele Diagnostics accepts samples Monday-Saturday excluding some holidays. Contact Allele Diagnostics regarding holiday schedules. Please include a complete copy of the appropriate Allele Diagnostics Requisition form: https://www.allelediagnostics.com/ordering/requisition/.
Order URL Help: https://www.allelediagnostics.com/ordering/order-test/

Specimen source

Amniocytes
Amniotic fluid
Cell culture
Chorionic villi
Cord blood
Cystic hygroma fluid
Fetal blood
Fresh tissue
Frozen tissue
Isolated DNA
Product of conception (POC)
Skin

Methodology

Help
Molecular Genetics
DDeletion/duplication analysis
Comparative Genomic Hybridization
HDetection of homozygosity
SNP Detection

Summary of what is tested

Click Methodology tab for more information.

Clinical utility

Help

Reproductive decision-making

Citations
  • Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies. - PubMed ID: 22865506
  • Chromosomal microarray versus karyotyping for prenatal diagnosis. - PubMed ID: 23215555
  • Committee Opinion No. 581: the use of chromosomal microarray analysis in prenatal diagnosis. - PubMed ID: 24264715

Guidance for management

Citations
  • Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies. - PubMed ID: 22865506
  • Clinical utility of chromosomal microarray analysis. - PubMed ID: 23071206
  • Chromosomal microarray versus karyotyping for prenatal diagnosis. - PubMed ID: 23215555
  • Committee Opinion No. 581: the use of chromosomal microarray analysis in prenatal diagnosis. - PubMed ID: 24264715

Establish or confirm diagnosis

Citations
  • Experience with microarray-based comparative genomic hybridization for prenatal diagnosis in over 5000 pregnancies. - PubMed ID: 22865506
  • Chromosomal microarray versus karyotyping for prenatal diagnosis. - PubMed ID: 23215555
  • Committee Opinion No. 581: the use of chromosomal microarray analysis in prenatal diagnosis. - PubMed ID: 24264715

Clinical validity

Help

Not provided

Testing strategy

Help

Microarray analysis reported within 2-4 business days if specimen is adequate. If not adequate, client will be contacted and plan established. After identification of a copy number gain or loss, FISH confirmation/visualization is attempted for majority of findings if specimen is adequate. If parental specimens are submitted with prenatal specimen, they are stabilized and available for follow-up testing after FISH is completed on prenatal sample. 000 For specimen requirements and handling instructions please visit: https://www.allelediagnostics.com/ordering/sample-requirements/. Allele Diagnostics accepts samples Monday-Saturday excluding some holidays. Contact Allele Diagnostics regarding holiday schedules. Please include a complete copy of the appropriate Allele Diagnostics Requisition form: https://www.allelediagnostics.com/ordering/requisition/.

Test services

Help
  • Custom Balanced Chromosome Rearrangement Studies, comments
  • Custom Deletion/Duplication Testing, comments
  • Maternal cell contamination study (MCC), Order code: 7500, comments
  • Cell culturing, comments

Practice guidelines

  • ACMG, 2021
    Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG)
  • NSGC, 2021
    National Society of Genetic Counselors Position Statement: Prenatal Cell-Free DNA Screening
  • ACMG, 2016
    Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics
  • ESHG/ASHG, 2015
    Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening.
  • NSGC, 2013
    Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. (Replaced by NSCG, 2021 Statement)
  • ACMG, 2013
    ACMG statement on noninvasive prenatal screening for fetal aneuploidy. (See 2016 Update)
  • ICFMM, 2013
    Position Statement from the Italian College of Fetal Maternal Medicine: Non-invasive prenatal testing (NIPT) by maternal plasma DNA sequencing.
  • NSGC, 2013
    NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy.

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.